Status:
COMPLETED
Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Asia. The aim of this clinical trial is to investigate the pharmacokinetic properties (the rate at which the trial drug is eliminated from the body) after a single subcutane...
Eligibility Criteria
Inclusion
- Considered generally healthy upon completion of medical history, physical examination, vital signs and electrocardiogram (ECG), as judged by the Investigator (the Physician)
- Body Mass Index (BMI): 19.0-24.0 kg/m2 (both inclusive)
Exclusion
- Clinically significant abnormal haematology, biochemistry, lipids or urinalysis screening tests, as judged by the Investigator (the Physician)
- A history of any illness that, in the opinion of the Investigator (the Physician), might confound the results of the trial or a pose risk in administering the trial product to the subject
- Subject who has donated any blood or plasma in the past month or more than 400 mL within 3 months prior to screening (trial entry)
- Not able or willing to refrain from smoking during the inpatient period
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01242826
Start Date
February 1 2011
End Date
March 1 2011
Last Update
May 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, Beijing Municipality, China, 100730